Argenx Se ADR (ARGX) Stock Price, Quote & News

Company Profile

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren'...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 10 703 8441

Website: argenx.com

Address:

Laarderhoogtweg 25, Amsterdam, Netherlands

G101SPM Oct. 27 at 7:11 PM

#SHOWTIME American Association of Neuromuscular and Electrodiagnostic Medicine Meeting (October 28-30) Scheduled to appear: $ARGX, $CPRX, $DNTH, $KYTX, $VOR

0 · Reply

moneybag888 Oct. 27 at 4:30 PM

$ARGX #BeFirst 🚀🚀🚀🚀😎

1 · Reply

moneybag888 Oct. 27 at 4:29 PM

$ARGX $900 EOM $1000+ EOY possible buyout too 😎

0 · Reply

LiquidThetaLEAPS Oct. 27 at 5:05 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ARGX Current Share Price: $817.32 Contracts: $ARGX July 17, 2026 $900 Calls Scale in: $73.16- $89.42 Scale out: $113.81-$146.32 Can Easily Capture: 60% ROI Blended DTE: 264 Days | Join Elites here: https://liquidtheta.com

0 · Reply

Travis1013 Oct. 26 at 3:11 PM

$ARGX Yes please!!!!

1 · Reply

moneybag888 Oct. 24 at 10:23 PM

$ARGX 🤣🤣🤣

0 · Reply

LiquidThetaOptions Oct. 24 at 4:46 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ARGX Current Share Price: $817.99 Contracts: $ARGX July 17, 2026 $900 Calls Scale in: $73.59- $89.94 Scale out: $114.47-$147.18 Can Easily Capture: 60% ROI Blended DTE: 267 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

moneybag888 Oct. 23 at 10:11 PM

$ARGX $1000 EOY

1 · Reply

Travis1013 Oct. 23 at 5:26 PM

$ARGX https://finance.yahoo.com/news/argenx-report-third-quarter-2025-050000372.html Predictions welcome!!

0 · Reply

moneybag888 Oct. 22 at 8:35 PM

$RIGL $ARGX $REGN 🚀🚀🚀

0 · Reply

argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session

Oct 3, 2025, 4:01 PM EDT - 24 days ago

argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

Sep 18, 2025, 9:00 AM EDT - 5 weeks ago

FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations

Sep 16, 2025, 9:23 PM EDT - 5 weeks ago

argenx SE - Special Call

Sep 12, 2025, 4:16 AM EDT - 6 weeks ago

argenx: Bullish On This R&D Focused Biotech Stock

Sep 8, 2025, 10:12 AM EDT - 7 weeks ago

Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 3:32 PM EDT - 7 weeks ago

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

BBH BMRN CYTK IBB XBI

Aug 28, 2025, 1:00 AM EDT - 2 months ago

argenx to Present at Upcoming Investor Conferences

Aug 26, 2025, 1:35 PM EDT - 2 months ago

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Aug 25, 2025, 1:00 AM EDT - 2 months ago

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

Aug 19, 2025, 1:00 AM EDT - 2 months ago

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

Aug 12, 2025, 6:45 AM EDT - 2 months ago

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis

Aug 7, 2025, 9:35 PM EDT - 2 months ago

Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts

COO ELV HQY IDXX INSM ISRG RDNT

Aug 1, 2025, 8:31 AM EDT - 3 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN AZN BAX BIIB

Aug 1, 2025, 6:54 AM EDT - 3 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN AZN BAX BIIB

Jul 31, 2025, 1:22 PM EDT - 3 months ago

argenx SE (ARGX) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 1:00 AM EDT - 3 months ago

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

Jul 24, 2025, 1:00 AM EDT - 3 months ago

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

Jun 30, 2025, 1:13 PM EDT - 4 months ago

FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls

Jun 20, 2025, 1:00 PM EDT - 4 months ago

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

Jun 10, 2025, 6:01 PM EDT - 4 months ago

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease

Jun 3, 2025, 1:00 AM EDT - 5 months ago

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025, 4:01 PM EDT - 5 months ago

argenx Announces Results of Annual General Meeting of Shareholders

May 9, 2025, 8:02 AM EDT - 6 months ago

Argenx Q1 Earnings: Less Than Perfect Report Gets Punished

May 8, 2025, 8:16 PM EDT - 6 months ago

argenx SE (ARGX) Q1 2025 Earnings Call Transcript

May 8, 2025, 1:00 AM EDT - 6 months ago

argenx Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 1:00 AM EDT - 6 months ago

argenx to Present at BofA Securities 2025 Health Care Conference

May 1, 2025, 1:00 AM EDT - 6 months ago

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

Apr 28, 2025, 1:00 AM EDT - 6 months ago

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Apr 11, 2025, 5:41 PM EDT - 7 months ago

FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting

Apr 11, 2025, 4:01 PM EDT - 7 months ago

argenx Announces Annual General Meeting of Shareholders on May 27, 2025

Apr 10, 2025, 5:59 PM EDT - 7 months ago

US FDA approves syringe version of Argenx's immune disorder drug

Apr 10, 2025, 5:47 PM EDT - 7 months ago

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 8, 2025, 1:00 AM EDT - 7 months ago

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

Apr 4, 2025, 2:30 PM EDT - 7 months ago

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI CCL CEPU CF CROX CUK DECK

Mar 7, 2025, 1:00 AM EST - 8 months ago

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

Feb 27, 2025, 3:17 PM EST - 8 months ago

argenx SE (ARGX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:58 AM EST - 8 months ago

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

Feb 27, 2025, 1:00 AM EST - 8 months ago

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

Feb 25, 2025, 1:00 AM EST - 8 months ago

argenx to Present at TD Cowen 45th Annual Healthcare Conference

Feb 20, 2025, 1:00 AM EST - 8 months ago

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

Jan 13, 2025, 1:00 AM EST - 10 months ago

argenx Highlights 2025 Strategic Priorities

Jan 6, 2025, 1:00 AM EST - 10 months ago

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 27, 2024, 1:00 AM EST - 10 months ago

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Nov 20, 2024, 1:00 AM EST - 1 year ago

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Nov 19, 2024, 9:10 AM EST - 1 year ago

Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics

Nov 11, 2024, 7:30 AM EST - 1 year ago

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Nov 11, 2024, 7:30 AM EST - 1 year ago

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

ZLAB

G101SPM Oct. 27 at 7:11 PM

#SHOWTIME American Association of Neuromuscular and Electrodiagnostic Medicine Meeting (October 28-30) Scheduled to appear: $ARGX, $CPRX, $DNTH, $KYTX, $VOR

0 · Reply

moneybag888 Oct. 27 at 4:30 PM

$ARGX #BeFirst 🚀🚀🚀🚀😎

1 · Reply

moneybag888 Oct. 27 at 4:29 PM

$ARGX $900 EOM $1000+ EOY possible buyout too 😎

0 · Reply

LiquidThetaLEAPS Oct. 27 at 5:05 AM

0 · Reply

Travis1013 Oct. 26 at 3:11 PM

$ARGX Yes please!!!!

1 · Reply

moneybag888 Oct. 24 at 10:23 PM

$ARGX 🤣🤣🤣

0 · Reply

LiquidThetaOptions Oct. 24 at 4:46 PM

0 · Reply

moneybag888 Oct. 23 at 10:11 PM

$ARGX $1000 EOY

1 · Reply

Travis1013 Oct. 23 at 5:26 PM

$ARGX https://finance.yahoo.com/news/argenx-report-third-quarter-2025-050000372.html Predictions welcome!!

0 · Reply

moneybag888 Oct. 22 at 8:35 PM

$RIGL $ARGX $REGN 🚀🚀🚀

0 · Reply

moneybag888 Oct. 22 at 2:51 PM

$ARGX road to $900 and $1009 #BeFirst 😎

0 · Reply

moneybag888 Oct. 21 at 9:55 PM

$RIGL $ARGX $REGN 🚀🚀🚀🚀🚀🚀

0 · Reply

LiquidThetaOptions Oct. 20 at 3:12 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ARGX Current Share Price: $843.66 Contracts: $ARGX July 17, 2026 $900 Calls Scale in: $50.76- $62.04 Scale out: $78.96-$101.52 Can Easily Capture: 60% ROI Blended DTE: 271 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

LiquidThetaOptions Oct. 18 at 5:56 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ARGX Current Share Price: $837.28 Contracts: $ARGX July 17, 2026 $900 Calls Scale in: $50.76- $62.04 Scale out: $78.96-$101.52 Can Easily Capture: 60% ROI Blended DTE: 273 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

moneybag888 Oct. 17 at 8:58 PM

$ARGX 🤣🤣🤣😎

0 · Reply

moneybag888 Oct. 17 at 7:02 PM

$ARGX @CDMO 😎🚀🚀🚀

0 · Reply

CDMO Oct. 17 at 7:01 PM

$ARGX sold all my $PFE in april to buy $ARGX. was a good choice. Pfe is such a dog

1 · Reply

moneybag888 Oct. 17 at 6:59 PM

$ARGX 5% more 😎

0 · Reply

moneybag888 Oct. 17 at 6:47 PM

$HNST be like $ARGX slow and steady

1 · Reply

moneybag888 Oct. 17 at 6:46 PM

$ARGX $846.98 ATH

0 · Reply

moneybag888 Oct. 17 at 6:41 PM

$S fckng management… still holding for BUYOUT… be like $ARGX moving slow and steady…

0 · Reply

moneybag888 Oct. 17 at 6:39 PM

$ARGX 🚀🚀🚀🚀

0 · Reply

Market Cap	50.32B
Revenue (ttm)	2.25B
Net Income (ttm)	833.04M
EPS (ttm)	N/A
PE Ratio	87.43
Forward PE	50.54
Profit Margin	36.99%
Debt to Equity Ratio	0.00

Volume	342,638
Avg Vol	360,152
Day's Range	N/A - N/A
Shares Out	61.57M
Stochastic %K	38%
Beta	0.46
Analysts	Strong Sell
Price Target	$843.04